SCHEMBL8213534

SCHEMBL8213534

Cn1nc(-c2ccc(O)cc2)c(-c2nccs2)n1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 1/20 0.40
▸ ESR2 Q92731 1/20 0.40
▸ SYK P43405 1/20 0.40
▸ FBP1 P09467 1/20 0.40
▸ ADRB2 P07550 1/20 0.39
▸ PDPK1 O15530 1/20 0.39
▸ LOXL2 Q9Y4K0 1/20 0.38
▸ SMPD3 Q9NY59 1/20 0.38
▸ ADORA1 P30542 8/20 0.37
▸ ADORA2A P29274 7/20 0.37
▸ ADORA3 P0DMS8 4/20 0.37
▸ ECE1 P42892 1/20 0.35
▸ CYP2A6 P11509 1/20 0.35
▸ ADORA2B P29275 3/20 0.35
▸ ABL1 P00519 1/20 0.35
▸ BCR P11274 1/20 0.35
▸ HSP90AA1 P07900 1/20 0.34
▸ CYP19A1 P11511 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8214626 0.84 PDPK1 (0.58) ADRB2PDPK1LOXL2ADORA1ADORA2A
SCHEMBL8205594 0.82 GABRA1 (0.47) FBP1SMPD3ECE1ABL1BCR
SCHEMBL466426 0.76 PDPK1 (0.63) ESR1ESR2SYKFBP1ADRB2
SCHEMBL3270763 0.75 BRAF (0.50) CYP19A1
Ammonia Solution, Strong SCHEMBL29239355 0.75 PDPK1 (0.61) ESR1ESR2SYKFBP1ADRB2
SCHEMBL8220878 0.72 ALOX15 (0.50) ESR1ESR2
SCHEMBL13510669 0.70 PDPK1 (0.54) ESR1ADRB2PDPK1LOXL2ADORA1
SCHEMBL10678369 0.69 ESR1 (0.39) ESR1ESR2ADORA1ADORA3
SCHEMBL10072211 0.69 GABRA1 (0.43) FBP1ADRB2LOXL2SMPD3ADORA1
SCHEMBL13509018 0.69 PDPK1 (0.53) ADRB2PDPK1ADORA1ADORA2AADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008021871-A2 TRIAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2008-02-21 — — WO disclosed
Send feedback